Tectonic Therapeutic, Inc.
Tectonic Therapeutic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs). Its proprietary GEODe™ platform is designed to support discovery of biologic drugs targeting GPCRs. The company’s programs include TX45, an Fc-relaxin fusion molecule being studied for Group 2 pulmonary hypertension associated with heart failure and Group 3 pulmonary hypertension associated with interstitial lung disease; TX2100, an APJ receptor antagonist antibody being developed for hereditary hemorrhagic telangiectasia; and a bispecific GPCR modulator program for fibrotic diseases. Tectonic develops product candidates for potential medical use and, at its current stage, has not established commercial or distribution capabilities. It relies on third-party contract development and manufacturing organizations to produce candidates for preclinical and clinical testing. Tectonic is headquartered in Watertown, Massachusetts.
No SEC Form 4 filings for $TECX in the last 30 days.
See all $TECX insider activity →Tectonic Therapeutic (TECX) reported Q3 GAAP EPS of -$1.08, beating estimates by $0.24. The company had $234.7M in cash as of September 30, 2026, with a runway into Q1 2029. This includes $22.3M from a recent offering.
Tectonic Therapeutic, Inc. (TECX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Tectonic Therapeutic Announces Third Quarter 2026 Financial Results and Recent Business Highlights • Reported favorable safety, tolerability and pharmacokinetic (“PK”) results from the single ascending-dose portion of the TX2100 Phase 1a clinical trial in healthy adu
Analysts from Piper Sandler and other firms maintained Buy ratings on Tectonic Therapeutic (TECX), Boston Scientific (BSX), and Liquidia Technologies (LQDA). Price targets set at $76 for TECX, $60 for BSX, and $58 for LQDA. Current share prices and analyst consensus also provided.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning TECX (Tectonic Therapeutic, Inc.). Coverage has skewed bullish: 2 bullish, 1 neutral, and 0 bearish.
Recent TECX coverage spans financial news, technology and earnings.
Earnings beat and strong cash position suggest upside potential.
Positive early‑stage data and regulatory Fast‑Track status are likely to lift sentiment and drive short‑term buying pressure.
Analyst upgrade with higher price target may lift sentiment.
Neutral rating may temper bullish sentiment, leading to modest downside pressure.
Positive trial data and regulatory milestone likely lift sentiment and attract investor interest.
AlphAI scores every news story that mentions TECX with an AI model for sentiment and relevance, and aggregates insider trades from Tectonic Therapeutic, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Tectonic Therapeutic (TECX) reported Q3 GAAP EPS of -$1.08, beating estimates by $0.24. The company had $234.7M in cash as of September 30, 2026, with a runway into Q1 2029. This includes $22.3M from a recent offering.
Tectonic Therapeutic, Inc. (TECX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Tectonic Therapeutic Announces Third Quarter 2026 Financial Results and Recent Business Highlights • Reported favorable safety, tolerability and pharmacokinetic (“PK”) results from the single ascending-dose portion of the TX2100 Phase 1a clinical trial in healthy adu
Analysts from Piper Sandler and other firms maintained Buy ratings on Tectonic Therapeutic (TECX), Boston Scientific (BSX), and Liquidia Technologies (LQDA). Price targets set at $76 for TECX, $60 for BSX, and $58 for LQDA. Current share prices and analyst consensus also provided.
UBS initiated coverage of Tectonic Therapeutic (TECX) with a Neutral rating and $26 price target, citing challenges in Phase 3 trials for TX45. The analyst notes that the six-minute walk distance endpoint is more demanding than Phase 2 metrics.
Tectonic Therapeutic, Inc. (TECX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT) • U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investig
Tectonic Therapeutic (TECX) reported Q2 results, highlighting progress in two clinical trials, TX45 for pulmonary hypertension and TX2100 for a rare bleeding disorder. The company has sufficient cash to fund operations into 2029. Net loss widened to $22.3M from $20M a year earlier. Hedge fund ownership increased, while short interest remains high at 17.86% of the float.
Analysts reiterated Buy ratings on Amgen (AMGN), Tectonic Therapeutic (TECX), and Revolution Medicines (RVMD). Amgen has a $394.73 avg. price target, Tectonic $79.50, and Revolution $241.70. Analysts cited in reports include Matt Phipps, Uy Ear, and Laura Prendergast.
Tectonic Therapeutic, Inc. (TECX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights • Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-
Biotech gainers included SL Science (SLBT), up 34.61% to $5.99 after Nasdaq trading began June 15; Chemomab (CMMB), up 33.53% to $2.27 as Phase 3 preparations for Nebokitug in primary sclerosing cholangitis continue; Propanc (PPCB), up 22.92% to $1.77 after a $500k buyback authorization. Also: VERAXA (VRXA) +18.26% to $2.04 with ATUM support; Tectonic (TECX) +15.85% to $37.93 ahead of Phase 2/1 catalysts; Aura (AURA) +15.01% to $7.74 ahead of bel-sar data; SELLAS (SLS) +12.89% to $14.98 with REG
Tectonic Therapeutic (NASDAQ: TECX) said it completed enrollment in its 24-week APEX Phase 2 trial of TX45 for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The trial enrolled 191 patients in 14 countries, with ~72% in CpcPH patients (PVR >3 WU). Topline results are expected in early Q1 2027.
